

**COMMONWEALTH OF KENTUCKY
CABINET FOR HEALTH AND FAMILY SERVICES
DEPARTMENT FOR MEDICAID SERVICES
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING**

Capitol Annex – Room 131

700 Capital Avenue Frankfort, Kentucky 40601

Thursday, November 21, 2019

1:00 P.M. to 4:00 P.M.

AGENDA

- I. Call to Order and Welcome**
- II. Executive Session (upon request)**
- III. Old Business**
 - a. Approval of Meeting Minutes
- IV. New Business**
 - a. New Products to Market to be reviewed as single products:
 - i. Inrebic[®] (Oncology, Oral – Hematologic)
 - ii. Xpovio[™] (Oncology, Oral – Hematologic)
 - iii. Rozlytrek[™] (Oncology, Oral – Lung)
 - iv. Turalio[™] (Oncology, Oral – Other)
 - v. Nubeqa[®] (Oncology, Oral – Prostate)
 - vi. Sunosi[™] (Stimulants and Related)
 - b. New Products to Market to be reviewed along with their respective classes:
 - i. Rinvoq[™] (Cytokines and CAM Antagonists)
 - ii. Zolgensma[™] (Spinal Muscular Atrophy)
- V. Clinical Criteria Review (to occur within their respective class reviews)**
 - a. Multiple Sclerosis Agents Clinical Criteria for Preferred Agents
 - b. Ophthalmics, Glaucoma Agents (Other) Clinical Criteria for Preferred Agents
- VI. Therapeutic Classes with Recommended Changes**
 - a. Acne Agents, Topical
 - b. Antidiarrheals
 - c. Antiemetic/Antivertigo Agents
 - i. Anti-Emetics: Other
 - ii. Oral Anti-Emetics: 5-HT3 Antagonists
 - iii. Oral Anti-Emetics: NK-1 Antagonists
 - iv. Oral Anti-Emetics: Δ -9-THC Derivatives
 - d. Antiparasitics, Topical
 - e. Cytokine and CAM Antagonists (includes new agent Rinvoq[™])
 - f. Multiple Sclerosis Agents
 - g. Ophthalmics, Glaucoma Agents
 - i. Ophthalmic Beta Blockers
 - ii. Ophthalmic Carbonic Anhydrase Inhibitors
 - iii. Ophthalmic Combinations for Glaucoma
 - iv. Ophthalmic Glaucoma Direct Acting Miotics

- v. Ophthalmic Prostaglandin Agonists
- vi. Ophthalmic Sympathomimetics
- vii. Ophthalmics, Glaucoma Agents (Other)
- h. Otic Antibiotics
- i. Proton Pump Inhibitors
- j. Spinal Muscular Atrophy (includes new agent Zolgensma™)
- k. Ulcerative Colitis Agents

VII. Consent Agenda

- a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

Acne Agents, Oral	Laxatives & Cathartics
Antibiotics, Topical	Ophthalmic Antibiotic-Steroid Combinations
Anticholinergics/Antispasmodics	Ophthalmic Antibiotics
Antifungals, Topical	Ophthalmics, Anti-Inflammatories
Antipsoriatics, Oral	Ophthalmics, Anti-Inflammatories-Immunomodulators
Antipsoriatics, Topical	Ophthalmics, Antiviral
Anti-Ulcer Protectants	Ophthalmics for Allergic Conjunctivitis
Antivirals, Topical	Ophthalmics, Mydriatic
Bile Salts	Ophthalmics, Vasoconstrictor
GI Motility, Chronic	Otic Anti-Infectives & Anesthetics
H. Pylori Treatment	Otics, Anti-Inflammatory
Histamine II Receptor Blockers	Rosacea Agents, Topical
Immunomodulators, Atopic Dermatitis	Steroids, Topical (High, Low, Medium, Very High)
Immunosuppressives, Oral	

VIII. Adjournment

- a. Schedule of Upcoming Meetings
 - i. **January 16, 2020**
 - ii. **March 19, 2020**
 - iii. **May 21, 2020**
- b. Collection of Travel Vouchers

PUBLIC SPEAKERS: If you would like to speak during the public session, please complete the Speaker Request Form located on the Committees/P&T tab of the Kentucky specific Magellan Medicaid Administration web portal at:

<https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml>.